AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.95M | -57.12M | -34.73M | -45.62M | -34.21M |
| Total Depreciation and Amortization | 7.92M | 7.24M | 7.06M | 6.61M | -18.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.50M | 15.43M | 12.06M | 17.00M | 29.41M |
| Change in Net Operating Assets | -46.22M | -18.14M | -16.80M | 10.46M | 14.90M |
| Cash from Operations | -34.74M | -52.59M | -32.40M | -11.55M | -8.00M |
| Capital Expenditure | -9.84M | -8.93M | -13.37M | -10.64M | -15.63M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 84.98M | 45.42M | -18.45M | 18.57M | 51.33M |
| Cash from Investing | 75.14M | 36.49M | -31.81M | 7.94M | 35.70M |
| Total Debt Issued | 10.52M | 7.55M | 5.51M | 6.15M | 4.32M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.41M | -182.00K | -8.88M | -178.00K | -177.00K |
| Cash from Financing | 4.12M | 7.37M | -3.38M | 5.97M | 4.14M |
| Foreign Exchange rate Adjustments | 290.00K | -544.00K | 761.00K | 590.00K | -2.16M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.80M | -9.28M | -66.83M | 2.94M | 29.69M |